UGA researchers in collaboration with Anacor Pharmaceuticals have received a $5.3 million grant from the Wellcome Trust to develop a new drug, which they hope will be ready to enter clinical trials by 2016, for the treatment of Chagas disease.
Chagas disease is caused by the parasite Trypanosoma cruzi,, which spreads via a subspecies of blood-feeding insects commonly known as “kissing bugs” because they tend to bite people on the face and lips. While the disease can progress slowly, chronic infection almost inevitably results in irreparable damage to heart and digestive system tissues.
Between 10 million and 20 million people, mostly in Central and South America, are infected with Trypanosoma cruzi. Chagas disease kills more people in Latin America than any other infectious disease including malaria, tuberculosis and HIV. An increasing number of cases also are being documented outside the normal high transmission areas, including in the U.S. and Europe.
“The two drugs commonly used to treat Chagas disease-benznidazole and nifurtimox-require a long course of therapy and have a number of serious side effects,” said Rick Tarleton, the UGA Athletic Association Distinguished Research Professor of Biological Sciences in the cellular biology department in the Franklin College of Arts and Sciences. “This, combined with the fact that many isolates of the parasite are resistant to these existing drugs, emphasizes the tremendous need for new treatments.”
Tarleton’s laboratory will work in partnership with Anacor, a biopharmaceutical company focused on discovering, developing and commercializing novel small molecule therapeutics derived from its boron chemistry platform.
Anacor pioneered the development of a boron-based drug class called oxaboroles, which researchers hope will serve as the foundation for a new Chagas therapy.
“These new drug classes have a lot of potential for a variety of diseases, including many of the most neglected diseases of humans,” said Tarleton, who is a member of UGA’s Center for Tropical and Emerging Global Diseases. “We have worked with Anacor to identify some potent lead compounds for use in Chagas disease, and this funding will help turn those leads into effective drugs.”
